Noa Wertheimer
Director, Scientific Strategy EmendoBio
Noa Wertheimer, PhD, Director of Scientific Strategy at Emendo Biotherapeutics, bridges science and business to advance genome editing innovation. She earned her PhD in Molecular Biology from Tel Aviv University and has been with Emendo for five years. Noa leads strategic development of the company’s OMNI nuclease platform—comprising hundreds of novel enzymes mined from metagenomes—enabling flexible, next-generation editing solutions. She also supports partnerships and the expansion of technologies including prime and epigenome editing to broaden therapeutic applications.
Seminars
Tuesday 29th September 2026
Expanding Genome Accessibility Beyond SP-Cas9 Limitations Using AI-Enhanced Nuclease Platforms to Target Non-NGG PAM Sequences
11:30 am
- Addressing SP-Cas9 PAM sequence limitations that restrict targetability to only five percent of the human genome for conventional gene editing applications
- Leveraging AI-based technology to optimize diverse nuclease platforms recognizing alternative PAM sequences, reducing off-target activity and improving delivery compatibility for therapeutic applications
- Implementing AI-driven nuclease engineering to expand platform robustness and efficiency, enabling faster development of next-generation CRISPR tools including prime editors and base editors for therapeutic purposes
